he Alzheimer’s Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer’s disease.

BiOasis announces completion of a project intended to produce proprietary monoclonal antibodies for its Cognitest blood test for Alzheimer’s disease.

Five Flutemetamol abstracts featured at the 2011 Human Amyloid Imaging meeting.

Vermillion Inc, a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled “Biomarkers for Alzheimer’s disease” to the company.

Foundation Venture Capital Group hopes to help to lower the number of people living with Alzheimer’s disease. The company has made an initial investment to Durin Technologies Inc., a start-up company developing a test that requires only a drop of blood to diagnose the disease.

Scott and White Temple Hospital physician Arden L. Aylor, MD is one of three North American physicians who will help in the development and adoption of standard guidelines regarding dementia at the World Health Organization’s World Conference.

Several cerebrospinal fluid (CSF) biomarkers showed good accuracy in identifying patients with mild cognitive impairment who progressed to Alzheimer disease, according to a study in the July 22/29 issue of JAMA.

Transgenomic Inc and Power3 Medical Products Inc, have announced the clinical introduction of the NuroPro AD and NuroPro PD tests for Alzheimer’s and Parkinson’s disease at the 2009 American Academy of Neurology meeting in Seattle.

A test capable of confirming or ruling out Alzheimers disease has been validated and standardized by researchers at the University of Pennsylvania School of Medicine.